The technology described herein is directed to combinations and combinations for reducing the symptoms of digestive conditions, e.g., caused by ingestion of FODMAPs.

The present invention relates to polypeptides which are galacturonate (GalA) reductase variants comprising at least one amino acid substitution at a position corresponding to K261 and/or R267. The present invention further relates to nucleic acid molecules encoding the polypeptides and to host cells containing said nucleic acid molecules. The present invention further relates to a method for the production of L-galactonate (GalOA) and/or other bio-based compounds, comprising the expression of said nucleic acid molecules, preferably in said host cells. The present invention also relates to the use of the polypeptides, nucleic acids molecule or host cells for the production of L-galactonate (GalOA) and/or other bio-based compounds, and/or for the recombinant fermentation of biomaterial containing D-galacturonate (GalA).

A method for obtaining psicose from a mixture of fructose and psicose includes adding a mannitol dehydrogenase to a mixture of fructose and psicose to convert fructose into mannitol, and separating the mannitol from the psicose. Accordingly, the psicose can be more easily isolated from the mannitol with high efficiency by using the method.

A method for obtaining psicose from a mixture of fructose and psicose includes adding a mannitol dehydrogenase to a mixture of fructose and psicose to convert fructose into mannitol, and separating the mannitol from the psicose. Accordingly, the psicose can be more easily isolated from the mannitol with high efficiency by using the method.